Clinical Lipidology

Name: Clinical Lipidology
Author: Christie M. Ballantyne

A Companion to Braunwald’s Heart Disease

Specificaties

Gebonden, blz. | Engels

Elsevier Health Sciences | e druk, 2023

ISBN13: 9780323882866

Rubricering

Elsevier Health Sciences e druk, 2023 9780323882866

Onderdeel van serie Companion to Braunwald's Heart Disease

178,49

In winkelwagen

Verwachte levertijd ongeveer 9 werkdagen

Samenvatting

Part of the renowned Braunwald family of references, Clinical Lipidology: A Companion to Braunwald’s Heart Disease provides today’s clinicians with clear, authoritative guidance on the therapeutic management of patients with high cholesterol levels and other atherogenic lipid disorders. An invaluable resource for cardiologists, lipidologists, endocrinologists, and internal medicine physicians, this one-stop reference covers everything from basic science and the pathogenesis of atherothrombotic disease to risk assessment and the latest therapy options. Now fully updated from cover to cover, the 3rd Edition offers unparalleled coverage of lipidology in an accessible and user-friendly manner.Thoroughly covers the assessment, diagnosis, and treatment of patients with elevated levels of lipids and lipoproteins, including all the latest research-based recommendations, therapeutic breakthroughs, and related clinical advancesPresents the latest data on clinical guidelines, risk assessments, and established and emerging pharmacologic and nonpharmacologic therapies—all from internationally recognized experts in the fieldFeatures condensed, streamlined content that focuses on clinical applications and applying concepts to the practice setting. Chapters have now been completely reorganized into sections on risk assessment; therapy; new and evolving therapeutic targets and platforms; and special populationsIncludes new chapters on Polygenic Risk Scores; Inclisiran; Bempedoic Acid; Selective Peroxisome Proliferator–Activated Receptor–α Modulator: Pemafibrate; Evolving Therapeutic Targets: Lp(a), ANGPTL3, and ApoC-III; New Therapeutic Platforms: Gene Therapy and Genome Editing; and moreContains new or expanded content on inflammation; genetic testing; troponins for risk assessment; statins and role of bile acid sequestrants, niacin, and fibrates; mAbs; CANTOS and CIRT; colchicine; IL-6; and cellular, molecular, and genetic therapyProvides treatment algorithms throughout, as well as case vignettes that highlight the most common clinical questions in each chapterIncorporates the latest guidelines from the AHA, ACC, ESC, and EAS, as well as future directions for ongoing research and emerging applicationsEnhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices

Specificaties

ISBN13:9780323882866

Taal:Engels

Bindwijze:Gebonden

Uitgever:Elsevier Health Sciences

Serie:Companion to Braunwald's Heart Disease

Inhoudsopgave

SECTION I INTRODUCTION/BASIC MECHANISMS 1. Overview of Lipids and Atherosclerosis SECTION II RISK ASSESSMENT 2. Overview of Risk Assessment 3. Measurement of Low- Density Lipoprotein Cholesterol, Non–High- Density Lipoprotein Cholesterol, Apolipoprotein B, and Low- Density Lipoprotein Particle Concentration 4. Triglycerides, Triglyceride- Rich Lipoproteins, and High- Density Lipoprotein in Coronary Heart Disease Risk Assessment 5. Lipoprotein(a) in Cardiovascular Risk Assessment 6. Clinical Evaluation for Genetic Testing and Secondary Causes of Dyslipidemia 7. Polygenic Risk Scores 8. High- Sensitivity C- Reactive Protein 9. Emerging Assays for Risk Assessment 10. Imaging Atherosclerosis for Risk Stratifi cation: Cardiac Computed Tomography and Carotid Ultrasound SECTION III THERAPY 11. Overview of General Approach to Management of Dyslipidemias 12. Treatment Guidelines Overview: American Heart Association/American College of Cardiology/Multisociety Guideline and Updates 13. Treatment Guidelines Overview: European Society of Cardiology/European Atherosclerosis Society Guidelines 14. Dietary Patterns for the Prevention and Treatment of Cardiovascular Disease 15. Updated Clinical Guide to Exercise and Lipids 16. Obesity, Lipids, and Cardiovascular Disease 17. Statins 18. Cholesterol Absorption Inhibitors 19. Omega- 3 Fatty Acids 20. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition 21. Inclisiran 22. Bempedoic Acid 23. Pemafi brate: A New Selective Peroxisome Proliferator–Activated Receptor–_Modulator for Hypertriglyceridemia Management 24. Anti- inflammatory Therapy for Cardiovascular Disease 25. Nutraceuticals and Functional Foods for Cholesterol Reduction SECTION IV NEW AND EVOLVING THERAPEUTIC TARGETS AND PLATFORMS 26. Evolving Therapeutic Targets: Lipoprotein(a) 27. Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias 28. Evolving Therapeutic Targets: Apolipoprotein C- III 29. Evolving Therapeutic Targets: Cholesteryl Ester Transfer Protein Inhibition 30. Gene Therapy and Therapeutic Genome Editing in Liver for Lipid Disorders SECTION V SPECIAL PATIENT POPULATIONS 31. Special Patient Populations: Diabetes and Metabolic Syndrome 32. Special Patient Populations: Women and Older Adults 33. Special Patient Populations: Children and Adolescents 34. Special Patient Populations: Familial Hypercholesterolemia and Other Severe Hypercholesterolemias 35. Special Patient Populations: Treatment of Familial Chylomicronemia Syndrome and Sustained Chylomicronemia 36. Special Patient Populations: Acute Coronary Syndromes 37. Special Patient Populations: Transplant Recipients 38. Special Populations: Chronic Kidney Disease 39. Special Patient Populations: Lipid Abnormalities in High- Risk Racial/Ethnic Groups 40. Persons With Human Immunodeficiency Virus

Uw winkelwagen

Clinical Lipidology

A Companion to Braunwald’s Heart Disease

Samenvatting

Specificaties

Inhoudsopgave

Rubrieken

Personen

Trefwoorden